- To prospectively evaluate this hypothesis, all patients will be treated with enzalutamidein a manner similar to how short course ADT is used in common clinical practice. Half the patients will also be given PSA-TRICOM and PSA recovery after enzalutamide therapy will be compared between patients who received vaccine and those who did not.